- Product
- Generic substitutions and INN-based prescriptions on track
- by Kim JiEun Sep 4, 2025 06:12am
- The prolonged instability in drug supply has fueled momentum in the pharmacy community, with both streamlined generic substitutions and limited mandatory international nonproprietary name prescriptions gaining traction in the National Assembly. On September 2, Democratic Party of Korea lawmaker Jong-Tae Jang introduced amendments to the M
- Product
- Mounjaro arrives at pharmacies..₩310,000–350,000
- by Kang, Hye-Kyung Aug 21, 2025 06:07am
- Mounjaro (tirzepatide), which had been attracting considerable attention even before its arrival in Korea, has now been made available to pharmacies. With prescriptions also beginning on the 20th, pharmacies are bustling with activity. According to local pharmacies, two dosage forms, 2.5mg and 5mg, have begun arriving at pharmacies through wh
- Product
- Mounjaro set to hit shelves next week... pricing a dilemma
- by Jung, Heung-Jun Aug 13, 2025 06:07am
- With the imminent arrival of the diabetes and obesity treatment Mounjaro (tirzepatide) in Korea, pharmacies are struggling to set an appropriate price for the item. Due to the nature of high-priced non-reimbursable drugs, there are regional price differences, and price competition is expected in the future, so pharmacies are showing a
- Product
- Wegovy supply price cut by 40%... to counter Mounjaro
- by Kang, Hye-Kyung Aug 13, 2025 06:06am
- The supply price for Wegovy will be reduced by approximately 40% starting on the 14th. Refund measures are also expected to be implemented for pharmacies with inventory. Novo Nordisk notified pharmacies and other relevant parties of the changes through Julic and other channels. According to Dailypharm's coverage, the prices for four dosa
- Product
- Platforms promote Wegovy's lowest price is ₩390,000
- by Kang, Hye-Kyung Jul 30, 2025 06:10am
- Non-face-to-face treatment platforms are facing backlash from pharmacies after launching activities promoting the lowest prices for non-reimbursable drugs. Doctornow, a leading non-face-to-face medical consultation platform, is being criticized for encouraging price competition for non-reimbursable drugs and causing confusion among consumers.
- Product
- KPDS ‘Gov’t action needed to counter price hike pressure’
- by Jul 8, 2025 06:35am
- The Korean Pharmacists for Democratic Society (President: Kyung-Lim Jeon, KPDS) urged the government to take decisive action against Trump and multinational pharmaceutical companies' pressure to raise drug prices. In a statement released on the 4th, the KPDS stated: “Trump signed an executive order on May 12 demanding a reduction in drug
- Product
- 'Govn’t must take strong action against pharma rebates'
- by Kang, Hye-Kyung Jun 26, 2025 06:08am
- The Korean Pharmacists for Democratic Society (President Gyeong-rim Jeon, KPDS) has urged the government to take strong action against pharmaceutical company rebates. KPDS issued a statement regarding rebates made by a major domestic pharmaceutical company that JTBC reported. In the statement, KPDS said, “This is not an individual incide
- Product
- Patient organization proposes 6 policies as election pledges
- by Kang, Hye-Kyung May 14, 2025 06:10am
- A patient group has proposed six policies, including a “rapid reimbursement for new drugs and post-marketing adjustment system.” The Korea Alliance of Patients Organization submitted a 'Statement regarding Six Major Patient Policies' to political parties on the first day of the official campaign for the 21st presidential election on the
- Product
- Indiscriminate in-hospital prescriptions of Wegovy
- by Jung, Heung-Jun May 13, 2025 06:06am
- Criticism arose regarding the indiscriminate in-hospital prescriptions of Wegovy, which is currently allowed with an exception. According to the Korean Pharmaceutical Affairs Act, in-hospital prescription is allowed only when an 'injectable is injected.' However, it has been pointed out that Wegovy is being sold without a single act of inj
- Product
- Paxlovid transition to general health system effective June
- by Apr 11, 2025 06:01am
- Paxlovid, a treatment for COVID-19, will be transitioned to the general healthcare system starting in June. The free supply previously provided to centers designated for COVID-19 treatment (prescribing facilities) will be terminated entirely due to stock depletion. According to local pharmacists, on the 9th, various local public health
